Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
RZLT · against 589 other Healthcare companies listed in US-listed
Ranked #314 of 590 · scores higher than 3% of peers
Bars: peers in each 10-point band of the valuation score277 peers with a valuation score of 0–9, including RZLT · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | RZLT | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | -20.6% | -4.4% | 22% | 30% | |
| EBITDA yieldHigher is better · 578 reported | -33.2% | -0.8% | 15% | 50% | |
| Free cash flow yieldHigher is better · 554 reported | -20.9% | -2.3% | 17% | 20% | |
| Book yieldHigher is better · 587 reported | 28.7% | 26.6% | 54% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 253M USD | 98 | 80 | |
| 2 | 2.2B USD | 97 | 97 | |
| 3 | 563M USD | 96 | 97 | |
| 3 | 408M USD | 96 | 81 | |
| 3 | 322M USD | 96 | 57 | |
| 314 | 26.5B USD | 8 | 28 | |
| 314 | 38.1B USD | 8 | 34 | |
| 314 | 1.9B USD | 8 | 24 | |
| 314 | 7.2B USD | 8 | 32 | |
| 314 | 352M USD | 8 | 36 | |
| 314 | 701M USD | 8 | 11 | |
| 314 | 2.2B USD | 8 | 26 | |
| 314 | 422M USD | 8 | 40 | |
| 314 | 2.2B USD | 8 | 53 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score